| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -90,970 | -24,340 | -97,220 | -76,250 | -32,390 |
| Net Income Growth | -273.75% | +74.96% | -27.50% | -135.41% | -411.69% |
Filana Therapeutics Inc (FLNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Filana Therapeutics Inc. is a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system disorders, such as Tuberous Sclerosis Complex related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Filana Therapeutics Inc., formerly known as Cassava Sciences, Inc., is based in AUSTIN, Texas.
Fiscal Year End Date: 12/31